All In Biotech

Drug Trial Radar · NCT00954447

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy

Last checked: Nov 19, 2026Latest source record: Dec 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,263 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,263

Actual

Start

Aug 2009

Primary completion

Sep 2011

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Aug 7, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • PlaceboDrug

    Placebo, identical to Linagliptin tablet

  • LinagliptinDrug

    intended final marketed dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c After 24 WeeksTime frame: Baseline and 24 weeks

Locations

169 sites in 19 countries. Site status is shown where the registry gives one.

  • 1218.36.01043 Boehringer Ingelheim Investigational Site

    Escondido, California

  • 1218.36.01051 Boehringer Ingelheim Investigational Site

    Escondido, California

  • 1218.36.01065 Boehringer Ingelheim Investigational Site

    Fresno, California

  • 1218.36.01021 Boehringer Ingelheim Investigational Site

    Greenbrae, California

  • 1218.36.01013 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1218.36.01048 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1218.36.01058 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1218.36.01008 Boehringer Ingelheim Investigational Site

    Santa Ana, California

  • 1218.36.01056 Boehringer Ingelheim Investigational Site

    Waterbury, Connecticut

  • 1218.36.01054 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1218.36.01035 Boehringer Ingelheim Investigational Site

    Inverness, Florida

  • 1218.36.01010 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1218.36.01042 Boehringer Ingelheim Investigational Site

    New Port Richey, Florida

  • 1218.36.01063 Boehringer Ingelheim Investigational Site

    Pembroke Pines, Florida

  • 1218.36.01037 Boehringer Ingelheim Investigational Site

    Ponte Vedra, Florida

  • 1218.36.01032 Boehringer Ingelheim Investigational Site

    Saint Cloud, Florida

  • 1218.36.01049 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 1218.36.01036 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 1218.36.01047 Boehringer Ingelheim Investigational Site

    Decatur, Georgia

  • 1218.36.01009 Boehringer Ingelheim Investigational Site

    Roswell, Georgia

  • 1218.36.01055 Boehringer Ingelheim Investigational Site

    Honolulu, Hawaii

  • 1218.36.01014 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 1218.36.01011 Boehringer Ingelheim Investigational Site

    Paducah, Kentucky

  • 1218.36.01034 Boehringer Ingelheim Investigational Site

    City of Saint Peters, Missouri

  • 1218.36.01040 Boehringer Ingelheim Investigational Site

    Kansas City, Missouri

  • 1218.36.01029 Boehringer Ingelheim Investigational Site

    St Louis, Missouri

  • 1218.36.01018 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 1218.36.01053 Boehringer Ingelheim Investigational Site

    New Hartford, New York

  • 1218.36.01006 Boehringer Ingelheim Investigational Site

    Burlington, North Carolina

  • 1218.36.01025 Boehringer Ingelheim Investigational Site

    Hickory, North Carolina

  • 1218.36.01005 Boehringer Ingelheim Investigational Site

    Statesville, North Carolina

  • 1218.36.01015 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1218.36.01039 Boehringer Ingelheim Investigational Site

    Tulsa, Oklahoma

  • 1218.36.01019 Boehringer Ingelheim Investigational Site

    Altoona, Pennsylvania

  • 1218.36.01012 Boehringer Ingelheim Investigational Site

    Norristown, Pennsylvania

  • 1218.36.01004 Boehringer Ingelheim Investigational Site

    Greer, South Carolina

  • 1218.36.01020 Boehringer Ingelheim Investigational Site

    Simpsonville, South Carolina

  • 1218.36.01003 Boehringer Ingelheim Investigational Site

    Kingsport, Tennessee

  • 1218.36.01038 Boehringer Ingelheim Investigational Site

    Dallas, Texas

  • 1218.36.01016 Boehringer Ingelheim Investigational Site

    Houston, Texas

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.